1. Fig. 2 In vitro and preclinical study with 18F-MPG.
In vitro and preclinical study with 18F-MPG. (A) Quantitative uptake of 18F-MPG in four NSCLC cell lines and pretreatment with gefitinib. Data are means ± SD of three independent experiments. **P < 0.01 versus line-matched 18F-MPG uptake in HCC827 cells, Student’s t test. (B) The autoradiography and the same Western blot membrane stained with E746-A750–specific antibody. A single 18F-labeled protein band corresponds to the predominant band of ~175 kDa. Graphs next to the blots show densitometric quantification of autoradiogram band normalized to background. ***P < versus HCC827. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. (C) Decay-corrected whole-body coronal PET images of HCC827, H1975, H520, and H358 tumor-bearing mice at 30, 60, and 120 min after injection of 3.7 megabecquerels (MBq; 100 μCi) of 18F-MPG (red arrows indicate the location of the tumors). % ID/g, percentage of injected dose per gram. (D) Comparison of tumor/muscle ratios of 18F-MPG and 18F-FDG at 60 min after injection of 3.7 MBq (100 μCi) of tracer in different tumor-bearing mice (n = 6 per group) as measured by PET imaging. Data are means ± SD. ***P < versus line-matched 18F-MPG uptake in HCC827 cells, analysis of variance (ANOVA) with the Newman-Keuls multiple comparison test. 18F-FDG uptake versus 18F-MPG uptake in HCC827, ANOVA with the Newman-Keuls multiple comparison test.
Xilin Sun et al., Sci Transl Med 2018;10:eaan8840
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works